Is Gensight Biologics SA halal to invest in?

According to Musaffa's Shariah screening methodology, Gensight Biologics SA (SIGHT.PA) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Gensight Biologics SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Gensight Biologics SA using these criteria to determine its compliance status.

Can Muslims buy shares of Gensight Biologics SA?

Muslim investors may consider investing in Gensight Biologics SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Gensight Biologics SA classified as HALAL?

Musaffa determines the Shariah status of Gensight Biologics SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Gensight Biologics SA updated?

The Shariah compliance status of Gensight Biologics SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Gensight Biologics SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Gensight Biologics SA?

You can check the latest Shariah compliance status of Gensight Biologics SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Gensight Biologics SA SIGHT.PA

€0.09 €0.00 (2.24%) 1D

Last Updated: May 15, 12:00 AM·XPAR

SIGHT.PA Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: July 28, 2025

Report Source: 2024 Annual Report

Gensight Biologics SA. Stock Analysis SIGHT.PA

France Health Care Nano Cap Report: 2024 Annual

GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company employs 13 full-time employees The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

Key Statistics of Gensight Biologics SA (SIGHT.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.08€0.09

Today's Open

€0.09

Volume

485.24K

P/E Ratio (TTM)

52 Week Range

€0.08€0.27

Market Cap

19.97M

Avg. Volume

176.56K

Dividend Yield

Financial Metrics & Statements of Gensight Biologics SA (SIGHT.PA)

FAQ's for Gensight Biologics SA (SIGHT.PA)

According to Musaffa’s Shariah screening methodology, Gensight Biologics SA (SIGHT.PA) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.